Multiple-site bleeding with prominent rise in coagulation tests in an elderly woman using dabigatran etexilate

Cem Barçın, Hasan Kutsi Kabul, Emre Yağlancıkaya1, Mustafa Demir
Department of Cardiology, Gülhane Military Medical Faculty; Ankara-Turkey
1Department of Cardiology, Aksaz Military Hospital; Muğla-Turkey

Introduction

Dabigatran etexilate is a novel oral anticoagulant, which inhibits thrombin directly and offers an alternative to warfarin in atrial fibrillation (AF) (1-4). Dabigatran does not require routine blood testing or dose adjustments. However, increasing number of case reports show that dabigatran may change prothrombin time (PT) or activated partial thromboplastin time (aPTT) with clinical bleeding (5, 6). We, herein, report an elderly female who presented with multiple site bleeding and a dramatic increase in PT shortly after starting dabigatran.

Case Report

An 83-year-old woman (63 kg) who had been followed up for coronary artery disease and hypertension was hospitalized for pulmonary embolism and AF. After acute management in the coronary care unit we started warfarin and did not give aspirin upon the preference of the patient. During the follow up, she remained in AF. The PT was usually in target but she experienced asymptomatic increases in INR between 3.5 and 5 for a couple of times. After 9 months, she was hospitalized for bruising on the arm with PT (HemostIL™ RecombiPlas Tin2G) of 86 seconds and INR of 7.8. She was on warfarin 12.5 mg per week. Her creatinine was 0.95 mg/dL (with an estimated creatinine clearance (CrCl) of 44.6 mL/min), hemoglobin was 13.8 g/dL, and liver function tests were in normal range with the hemoglobin was 13.8 g/dL, and liver function tests were in normal range. We stopped warfarin and started Dabigatran Etexilate 110 mg b.i.d. after 10 days, the patient presented with severe subconjunctival hemorrhage, hematuria and hematoma in the right ankle. It had been nearly 24 hours after the last dabigatran dose and her INR was 14.8, PT was 163 seconds and aPTT was 71 seconds (Dade Actin Activated cephaloplastin reagent). Serum creatinine was 0.89 mg/dL (CrCl 47.6 mL/min) and liver tests were in normal range with the hemoglobin level of 12.4 g/dL. She was also using trimetazidine hydrochloride 35 mg b.i.d., metoprolol succinate 50 mg b.i.d., lercanidipine hydrochloride 10 mg q.d. and pantoprazol 40 mg q.d. We gave 3 units fresh frozen plasma in addition to 10 mg intravenous vitamin K. We ruled out lupus anticoagulants via mixing test. During follow up, INR reduced to 2.38 and aPTT reduced to 41 seconds. The Naranjo probability scale revealed a “probable” causality between the dabigatran and bleeding side effects. We discharged her with only aspirin of 300 mg/day.

Discussion

The present case shows that use of dabigatran etexilate may be associated with very high levels of coagulation tests even in relatively small doses in elderly patients with moderate renal impairment. Especially in case of hemorrhagic complications or in patients with high bleeding risk, it may be necessary to quantify the anticoagulant effects of dabigatran (7, 8). Dager et al. (9) showed that for every 25 ng/mL of dabigatran, INR increased 0.03 to 0.07 depending up the reagent and aPTT increased 4.6 seconds in average. In a similar study, Lindahl et al. (5) showed that 1000 ng/mL of serum dabigatran concentration resulted in INR between 1.4-4.5, and aPTT between 90-140 seconds with different reagents. In a recent case report, an increased INR level was found in a 79 year-old woman with CrCl of 20.7 mL/min/1.73 m2 (6). Harper et al. (10) observed 44 bleeding complications among 7000 patients. Two thirds of these patients were over 80 years old, more than 50% of these elderly patients had moderate renal impairment and nearly half of them weighed less than 60 kg. Our case had similarities to this patient profile with her age and renal function but the weight was not low and the main distinction was dramatically high level of PT, which was not the case in the study of Harper et al. (10).

Conclusion

Dabigatran etexilate must be used with caution especially in elderly patients. These patients should be followed up closely even if they do not have severely impaired renal impairment and low body weight. We also speculate that exaggerated levels of PT and aPTT may be “warning sign” in high-risk patients where other more specific coagulation tests for dabigatran are not available.

References


Address for Correspondence: Dr. Emre Yağlancıkaya, Aksaz Asker Hastanesi, Kardiyojoloji Bölümü, Marmaris, Muğla-Türkiye
Phone: +90 533 657 71 91
Fax: +90 312 304 42 50
E-mail: dremreyalcinkaya@gmail.com
Available Online Date: 09.06.2014
©Copyright 2014 by Turkish Society of Cardiology - Available online at www.anakarder.com
DOI:10.5152/akd.2014.5274